Thu, December 1, 2022
Wed, November 30, 2022
Tue, November 29, 2022

Amit Hazan Maintained (BVS) at Hold with Decreased Target to $2.5 on, Nov 30th, 2022

Amit Hazan of Goldman Sachs, Maintained "Bioventus Inc." (BVS) at Hold with Decreased Target from $13 to $2.5 on, Nov 30th, 2022.

Amit has made no other calls on BVS in the last 4 months.



There are 4 other peers that have a rating on BVS. Out of the 4 peers that are also analyzing BVS, 2 agree with Amit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Alexander Nowak of "Craig-Hallum" Downgraded from Strong Buy to Hold on, Tuesday, November 22nd, 2022
  • Kyle Rose of "Canaccord Genuity" Downgraded from Strong Buy to Hold on, Wednesday, November 9th, 2022


These are the ratings of the 2 analyists that currently disagree with Amit


  • Drew Ranieri of "Morgan Stanley" Maintained at Buy with Decreased Target to $5 on, Thursday, November 10th, 2022
  • Robbie Marcus of "JP Morgan" Downgraded from Buy to Sell on, Wednesday, November 9th, 2022